Intellia Therapeutics, based in Cambridge, MA, is a leading biotechnology company dedicated to transforming the lives of individuals with severe diseases through the development of potentially curative genome editing treatments.
With a focus on innovative CRISPR-based gene editing therapies, Intellia is committed to advancing cutting-edge science and research to address a range of genetic conditions, such as hereditary angioedema and ATTR amyloidosis, with the ultimate goal of making the impossible, possible for patients in need.
Generated from the website